Melanoma Research Victoria

Source: OncLive, July 2019 Five years out, one-third of patients with unresectable or metastatic BRAF V600-mutant melanoma remained alive following treatment with dual targeted therapy with dabrafenib (Tafinlar) plus trametinib (Mekinist), and 1 in 5 remained alive without progression, according to an analysis COMBI-d and COMBI-v trials reported at the 2019 ASCO Annual Meeting.1 Pooled data from […]

Read the full story

Source: ECancer News, July 2019 Igor Puzanov, MD, Director of the Early Phase Clinical Trials Program and Chief of Melanoma at Roswell Park Comprehensive Cancer Center, led research on the immunotherapy T-VEC, or talimogene laherparepvec, to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Dr. Puzanov is senior author […]

Read the full story

Source: ECancer News, July 2019 Igor Puzanov, MD, Director of the Early Phase Clinical Trials Program and Chief of Melanoma at Roswell Park Comprehensive Cancer Center, led research on the immunotherapy T-VEC, or talimogene laherparepvec, to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Dr. Puzanov is senior author […]

Read the full story

Source: Medscape Pharmacist, January 2019 An extensive analysis of a World Health Organization (WHO) global database has identified myocarditis, pericardial diseases, cardiac arrhythmias, and vasculitis as significant immune-related cardiac toxicities associated with the use of immune checkpoint inhibitors (ICIs) in routine clinical practice. These cardiotoxicities were seen more often in men than women. Pericardial diseases were more common […]

Read the full story